The European Medicines Agency (EMA) decision to relocate it's London HQ to Amsterdam is the latest post BrExit headline and the largest EU funded entity to be affected by the now historical vote.
With less than 18 months to execute the relocation of up to 900 roles, the team at EMA will undoubtedly face the challenges associated with relocating their talent in a forced move scenario, challenges that are very often magnified when compared to a relocation for promotion or developmental reasons.
If you too are preparing for a potential group move of staff, get ahead of the game by talking with your Relocation Management partner and review your policy provisions including the introduction of flexible and innovative solutions. At Plus Relocation, we have deep experience of managing similar projects and our website is a great starting resource hub for your planning.
EMA has to relocate due to the United Kingdom’s decision to withdraw from the EU. Amsterdam was one of 19 offers to host EMA submitted by the Member States at the end of July 2017. Today’s decision on EMA’s new location follows an assessment of the bids by the European Commission and EMA. The decision today marks the official start of a challenging joint relocation project that will have to be delivered within extremely tight timelines whereby the relocation has to be completed by 30 March 2019.